Related references
Note: Only part of the references are listed.Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis
Seth R. Flaxman et al.
LANCET GLOBAL HEALTH (2017)
Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register
Inger Westborg et al.
ACTA OPHTHALMOLOGICA (2017)
Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration Data from an Observational Study
Mark C. Gillies et al.
OPHTHALMOLOGY (2015)
Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
Irmela Mantel et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Juan E. Grunwald et al.
OPHTHALMOLOGY (2014)
NO CASES OF ENDOPHTHALMITIS AFTER 20,293 INTRAVITREAL INJECTIONS IN AN OPERATING ROOM SETTING
Troels Brynskov et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)
Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
Robert P. Finger et al.
SURVEY OF OPHTHALMOLOGY (2014)
Ten-Year Follow-up of Age-Related Macular Degeneration in the Age-Related Eye Disease Study AREDS Report No. 36
Emily Y. Chew et al.
JAMA OPHTHALMOLOGY (2014)
Four-Year Treatment Results of Neovascular Age-Related Macular Degeneration With Ranibizumab and Causes for Discontinuation of Treatment
Mads Kruger Falk et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Lutein plus Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial
Emily Y. Chew et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-related Macular Degeneration
Annette Rasmussen et al.
OPHTHALMOLOGY (2013)
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Soraya Rofagha et al.
OPHTHALMOLOGY (2013)
Smoking and Age-Related Macular Degeneration: Review and Update
Sara Velilla et al.
JOURNAL OF OPHTHALMOLOGY (2013)
Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Sara Brandi Bloch et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Michael A. Singer et al.
OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy
A. Kumar et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2011)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact
Omesh P. Gupta et al.
OPHTHALMOLOGY (2010)
The natural history and prognosis of neovascular age-related macular degeneration
Tien Wong et al.
OPHTHALMOLOGY (2008)
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration
Anne E. Fung et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2007)
Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration
David S. Boyer et al.
OPHTHALMOLOGY (2007)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization
Wael Soliman et al.
ACTA OPHTHALMOLOGICA SCANDINAVICA (2006)
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss - AREDS Report No. 8
A Kassoff et al.
ARCHIVES OF OPHTHALMOLOGY (2001)
Share Paper
